Biogen Inc
BIIB118.840USD
-0.670-0.56%
收盘 04/25, 16:00（美东）报价延迟15分钟
17.31B总市值
10.61市盈率 TTM
关于 Biogen Inc 公司
Biogen Inc. 是一家全球性生物制药公司。该公司致力于为全球患有严重和复杂疾病的人们发现、开发和提供先进的治疗方法。该公司经营一系列药物，用于治疗多发性硬化症 (MS)、脊髓性肌萎缩症 (SMA)、阿尔茨海默病和肌萎缩侧索硬化症 (ALS)。该公司专注于推进其在神经病学、专业免疫学和罕见疾病领域的产品线。其上市产品包括用于治疗 MS 的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用于治疗 SMA 的 SPINRAZA；用于治疗弗里德赖希共济失调的 SKYCLARYS；用于治疗 ALS 的 QALSODY 和用于治疗严重斑块状银屑病的 FUMADERM。它还与 Eisai 合作，将 LEQEMBI 商业化，用于治疗阿尔茨海默病，并与 Sage 合作，将 ZURZUVAE 商业化，用于治疗产后抑郁症 (PPD)。
公司简介
公司代码BIIB
公司名称Biogen Inc
上市日期Sep 17, 1991
成立日期1997
CEOMr. Christopher A. (Chris) Viehbacher
员工数量7605
证券类型Ordinary Share
年结日Sep 17
公司地址225 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话17814642000
网址https://www.biogen.com/
公司代码BIIB
上市日期Sep 17, 1991
成立日期1997
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
36.27K
+14.76%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
25.03K
+7.68%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.06K
+45.88%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
13.45K
+38.65%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
10.36K
-45.82%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.88K
+36.82%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
6.43K
+26.34%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
3.48K
+62.47%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
1.90K
+187.01%
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
36.27K
+14.76%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
25.03K
+7.68%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.06K
+45.88%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
13.45K
+38.65%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
10.36K
-45.82%
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Spinal Muscular Atrophy-SPINRAZA
1.99B
20.55%
MS product revenues-TYSABRI
1.72B
17.72%
MS product revenues-Fumarate
1.60B
16.49%
MS product revenues-Interferon
968.00M
10.00%
Biosimilar product revenues-BENEPALI
479.10M
4.95%
Other
2.93B
30.29%
地区USD
名称
营收
占比
Rest of World
3.98B
41.09%
United States
3.30B
34.08%
United states-Revenues from anti-CD20 therapeutic
1.75B
18.09%
Rest of World-Other revenues
652.60M
6.74%
业务
地区
业务USD
名称
营收
占比
Spinal Muscular Atrophy-SPINRAZA
1.99B
20.55%
MS product revenues-TYSABRI
1.72B
17.72%
MS product revenues-Fumarate
1.60B
16.49%
MS product revenues-Interferon
968.00M
10.00%
Biosimilar product revenues-BENEPALI
479.10M
4.95%
Other
2.93B
30.29%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
11.39%
PRIMECAP Management Company
10.96%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
5.05%
Wellington Management Company, LLP
3.37%
Other
63.35%
持股股东
股东统计
占比
The Vanguard Group, Inc.
11.39%
PRIMECAP Management Company
10.96%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
5.05%
Wellington Management Company, LLP
3.37%
Other
63.35%
股东类型
股东统计
占比
Investment Advisor
43.69%
Investment Advisor/Hedge Fund
36.85%
Hedge Fund
5.46%
Research Firm
2.82%
Pension Fund
2.29%
Bank and Trust
1.74%
Sovereign Wealth Fund
1.67%
Private Equity
0.35%
Individual Investor
0.15%
Other
4.99%
机构持股
更新时间: 1月20日 周一
更新时间: 1月20日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
2074
138.81M
94.83%
-5.05M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
2023Q1
2280
132.71M
91.84%
-5.88M
2022Q4
2292
132.00M
91.64%
-4.78M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
16.68M
11.39%
+1.13K
+0.01%
Dec 31, 2024
PRIMECAP Management Company
16.05M
10.96%
-268.87K
-1.65%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.59M
5.87%
+23.69K
+0.28%
Dec 31, 2024
State Street Global Advisors (US)
7.40M
5.05%
+53.29K
+0.73%
Dec 31, 2024
Wellington Management Company, LLP
4.93M
3.37%
-200.47K
-3.91%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.70M
2.52%
+82.46K
+2.28%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
3.10M
2.12%
-1.16M
-27.17%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
3.01M
2.06%
+40.53K
+1.36%
Feb 28, 2025
Pacer Advisors, Inc.
2.67M
1.82%
+2.65M
+13.57K%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
2.33M
1.59%
+246.45K
+11.86%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Invesco Biotechnology & Genome ETF
4.41%
iShares Neuroscience and Healthcare ETF
3.82%
Global X US Cash Flow Kings 100 ETF
3.55%
VanEck Biotech ETF
3.23%
Tema Neuroscience and Mental Health ETF
3.15%
Alger Russell Innovation ETF
3.04%
First Trust NYSE Arca Biotechnology Index Fund
2.94%
First Trust NASDAQ Pharmaceuticals ETF
2.89%
Invesco Pharmaceuticals ETF
2.39%
SPDR S&P Biotech ETF
2.19%
查看更多
Invesco Biotechnology & Genome ETF
占比4.41%
iShares Neuroscience and Healthcare ETF
占比3.82%
Global X US Cash Flow Kings 100 ETF
占比3.55%
VanEck Biotech ETF
占比3.23%
Tema Neuroscience and Mental Health ETF
占比3.15%
Alger Russell Innovation ETF
占比3.04%
First Trust NYSE Arca Biotechnology Index Fund
占比2.94%
First Trust NASDAQ Pharmaceuticals ETF
占比2.89%
Invesco Pharmaceuticals ETF
占比2.39%
SPDR S&P Biotech ETF
占比2.19%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据